Pfizer annoucned is reviewing options for its consumer health-care business, including a full or partial separation of the unit.

Pfizer said the consumer healthcare business, which had about $3.4 billion in revenue in 2016 and  produces Advil, Centrum, Emergen-C and other non-prescription items, was “distinct enough” from its core business that there could potential for it to be more valuable outside the company.

The company said any decision related to the options would be made during 2018.

“Pfizer Consumer Healthcare is a leading player in the largest OTC categories, with iconic brands, robust retail partnerships, global reach and strong fundamentals,” said Ian Read, Pfizer Chairman and Chief Executive Officer. “Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company. By exploring strategic options, we can evaluate how best to fuel the future success and expansion of Consumer Healthcare while simultaneously unlocking potential value for our shareholders.”

Source: CNBC